Osivelotor is an oral investigational drug for the treatment of sickle cell disease (SCD) designed to inhibit hemoglobin polymerization. In a phase 1, open-label ADME study conducted in healthy participants at ICON’s cli...
Thank you for your interest in ICON services. Please complete the form below providing details of your request, which will be sent to a member of staff for immediate review.
This form only accepts qualified proposal requests for ICON services. All other enquires should be directed to our Contact page.